Idiopathic pulmonary fibrosis
Vicore Pharma AB concentrates its clinical research on idiopathic pulmonary fibrosis, with studies centered on disease progression, respiratory function, and treatment effects in affected participants.
- Forced vital capacity
- Lung fibrosis
- Respiratory impairment
The sponsor’s work in this area is directed toward understanding therapeutic impact on pulmonary function in a chronic fibrotic lung disease.
Oral small-molecule therapy
Its research portfolio includes clinical evaluation of an oral small-molecule treatment candidate, with attention to formulation, safety, and pharmacokinetic behavior in human participants.
- Buloxibutid
- Oral formulations
- Pharmacokinetics
This area reflects interest in treatments designed for systemic administration and long-term use in fibrotic lung disease.
Drug metabolism and interaction science
Vicore Pharma AB also studies how its candidate therapies behave in the presence of metabolic pathway modulation, with a focus on drug-drug interactions and enzyme-related exposure changes.
- CES2 inhibition
- CYP3A4 inhibition
- Metabolic profiling
These investigations support interest in hepatic metabolism and the clinical handling of orally administered agents.
Safety and tolerability assessment
The sponsor’s trials include evaluation of safety and tolerability in healthy volunteers and patients, with emphasis on human exposure and treatment acceptability.
- Healthy volunteers
- Adverse event monitoring
- Clinical safety
This area supports the development of therapies intended for use in chronic respiratory disease.
